Home' Australian Pharmacist : Australian Pharmacist November 2012 Contents 912 Australian Pharmacist November 2012 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
two or less. An authority is required for
the PBS script.1 It is indicated for use,
in combination with prednisone or
prednisolone, for the treatment of patients
with hormone-refractory metastatic
prostate cancer previously treated with a
docetaxel-containing regimen.2 Cabazitaxel
is a semi-synthetic taxane, an antineoplastic
agent. It acts by disrupting the microtubular
network in cells. It binds to tubulin and
promotes the assembly of tubulin into
microtubules while simultaneously
inhibiting their diassembly. This leads to the
stabilisation of microtubules which results
in the inhibition of mitosis. Cabazitaxel is
active in docetaxel-sensitive tumours. In
addition, it demonstrated activity in tumour
models insensitive to chemotherapy,
1. Pharmaceutical Benefits Scheme. 1 Aug 2012
2. Jevtana Approved Product Information. Dec 2011
Sano Consumer Healthcare
Sanofi Consumer Healthcare has
introduced a new web tool to assist
consumers monitor the pollen count in
their capital city. Launched as part of
Telfast's website, the allergy forecaster
will enable Hayfever sufferers to get a
four-day pollen forecast. Mike Abbott,
Head of Marketing for Sanofi Consumer
Healthcare said, 'a major insight from
our research is that consumers delay
treatment to see if their symptoms will
subside. With fast acting, 24-hour relief
available, consumers are able to block hay
fever-causing allergens and treat their
symptoms before they take the fun out of
their life,' he said. The 4-day forecast is also
available through the Telfast Facebook
page (See www.telfast.com.au or www.
facebook.com/TelfastAU) which enables
consumers to automatically receive their
capital city forecast on their news feed
"As well as assisting consumers manage
their hayfever, the new social media
presence we have created will be a handy
reference point for pharmacies, giving
staff more opportunities to engage
with hayfever sufferers." Telfast has also
launched a television commercial which
will air throughout the hay fever season.
Australian Pharmacist is a professional journal providing community pharmacists with a
range of peer reviewed articles that are interesting and evidence-based to ensure credibility
and accuracy. The journal has an extremely strong CPD program followed by nearly 10,000
pharmacists and a typical monthly article receives more than 2950 assessments, with highs
Read in greater detail and more regularly than any other pharmacy title -- such constant
behaviour means you can count on our readers to open any issue and be seen!
» Read by 65% of community pharmacists
» The most valued and used for clinical information, continuing education, prescription
medicines, scheduled medicines, professional services and patient counselling
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2012
Adding the best read pages in pharmacy media to your campaign will result in greater
impact, leading to greater recognition -- package with the Australian Pharmacist
eBulletin to gain further recognition with 12,000 community pharmacists and high
open rates of 30%.
Ph: 02 9988 4689
Ph: 02 9547 3001
*Competitive Advantage Research August 2012 -- 632 practicing community pharmacists
Bacterial conjunctivitis in pharmacy
Pharmacists know how common bacterial conjunctivitis is amongst
When the pharmacist suspects or knows a customer has bacterial conjunctivitis, treatment
with Chlorsig (chloramphenicol) may be appropriate.1
To help pharmacy customers use Chlorsig correctly, Aspen have available patient
information sheets -- "Helpful information for patients using Chlorsig eye drops and
Available in tear-off pads of 25, the sheets are easy for
customers to read and provide useful information on
the condition of bacterial conjunctivitis, as well as an
overview of what Chlorsig is and how it should be
used and stored. The sheets are also a useful tool to
educate pharmacy assistants as to when to consult the
To order just ask your Aspen Rep or simply go to the
website - www.aspenpharma.com.au/chlorsig, using
the password 'profitable'.
1. Chlorsig Product Information (October 2010) ®Chlorsig is a registered
trademark of Aspen Pharma Pty Ltd.
Helpful information for patients using
Chlorsig eye drops and eye ointment
This document is intended as a guide only. Full Consumer Medicine Information is
available from your pharmacist.
What is Chlorsig?
Chlorsig is an antibiotic used to treat bacterial conjunctivitis -- a bacterial infection
involving the mucous membrane on the surface of the eye.
Chlorsig is available as both eye drops and eye ointment and is for external use only.
Ask your doctor, pharmacist or optometrist if you have any questions about why Chlorsig
has been prescribed for you. They may have prescribed it for another purpose.
About bacterial conjunctivitis
Bacterial conjunctivitis is an infection of the eye. The most common symptom is the
presence of a sticky yellow-white discharge with mucus and pus (or glued eyes,
especially in the morning on waking). Other symptoms include a gritty sensation in the
eye, redness, irritation and watering of the eyes.
The infection usually starts in one eye and then spreads to the other.
How to use Chlorsig
Chlorsig eye drops:
For adults and children (2 years and over): Instil 1 or 2 eye drops in the affected
eye(s) every two to six hours for up to 5 days or as directed by your doctor,
optometrist or pharmacist.
When applying eye drops gently pull down the lower lid to form a
pouch. Apply one drop into the pouch being careful not to let the
tip of the dropper touch the eye, eyelids or lashes. Close your eyes
and try not to blink for a short time. If instilling more than one drop,
Links Archive Australian Pharmacist December 2012 Australian Pharmacist October 2012 Navigation Previous Page Next Page